GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Quanterix Corporation
Quanterix has developed an ultra-sensitive platform for detecting biomarkers in blood. Its stock price reflects its potential for early diagnosis of diseases such as Alzheimer's and drug development. The chart tells the story of the commercialization of this breakthrough technology.
Share prices of companies in the market segment - Diagnostic medical equipment
Quanterix (QTRX) has developed the ultra-sensitive Simoa biomarker measurement platform, which enables the detection of proteins at ultra-low concentrations for early diagnostics and research. We classify it as "Diagnostic Medical Equipment." The chart below shows the dynamics in the diagnostics sector.
Broad Market Index - GURU.Markets
Quanterix has developed a highly sensitive platform for measuring blood biomarkers, opening up new possibilities in diagnostics. Its technology makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Quanterix compares to it.
Change in the price of a company, segment, and market as a whole per day
QTRX - Daily change in the company's share price Quanterix Corporation
The daily fluctuations of Quanterix, a developer of ultra-sensitive diagnostic tests, reflect progress in medicine. Change_co measures the volatility associated with the implementation of its platform in research. System.GURU.Markets uses this metric to evaluate innovative companies in the diagnostics sector.
Daily change in the price of a set of shares in a market segment - Diagnostic medical equipment
Quanterix Corporation is a company in the field of ultra-sensitive diagnostics. This chart illustrates the high volatility of the life sciences sector. Comparing it to QTRX's performance helps us understand how much its growth depends on R&D budgets and the implementation of its technology.
Daily change in the price of a broad market stock, index - GURU.Markets
Quanterix is the maker of a platform for ultra-sensitive protein analysis. Its technology is used for early disease diagnosis. The chart below shows overall market volatility, which can be used to assess how the market is responding to breakthrough technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Quanterix Corporation
Quanterix Corporation's year-over-year performance is a story of a revolution in biomarkers. Its 12-month market cap growth reflects pharmaceutical companies' demand for its highly sensitive Simoa protein detection platform, which enables earlier diagnosis of diseases such as Alzheimer's and evaluation of the effectiveness of new drugs.
Annual dynamics of market capitalization of the market segment - Diagnostic medical equipment
Quanterix Corporation is a company that has developed an ultra-sensitive biomarker detection platform that is transforming approaches to disease diagnosis. This chart shows how its breakthrough technology, growing adoption in research, and path to clinical application are impacting its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Quanterix, with its ultra-sensitive diagnostic platform, is a bet on the future of medicine. Its stock price isn't tied to the economy, but rather driven by scientific breakthroughs and partnerships. Its chart tells the story of investors' faith that its technology will revolutionize early disease detection.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Quanterix Corporation
The market capitalization of Quanterix, a proteomics company, depends on R&D cycles. Monthly fluctuations on the chart reflect demand for its ultra-sensitive protein analysis instruments from research labs, which are used in neurological disease and cancer research.
Monthly dynamics of market capitalization of the market segment - Diagnostic medical equipment
Quanterix has developed an ultra-sensitive platform for detecting biomarkers in blood, opening up new possibilities in the early diagnosis of diseases ranging from neurology to oncology. The graph below shows the overall dynamics in the diagnostic equipment sector, where Quanterix is a technology leader.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Quanterix Corporation develops a platform for ultra-sensitive biomarker analysis. The company's technology is used in drug research. Its stock price is driven by pharmaceutical industry R&D budgets and scientific breakthroughs, making its movement more closely tied to the innovation cycle than the market cycle.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Quanterix Corporation
Shares of Quanterix, a developer of ultra-sensitive diagnostic tests, reflect progress in biomedical research. Weekly price movements are driven by news about the use of its platform in the study of Alzheimer's and other diseases. The chart below shows how short-term scientific breakthroughs influence the company's valuation.
Weekly dynamics of market capitalization of the market segment - Diagnostic medical equipment
How does Quanterix's performance compare to the diagnostic equipment sector? The chart below compares the company's weekly stock price movements with the industry average. This helps us understand whether the company reacts more strongly than its competitors to news of scientific breakthroughs using its platform, or whether it follows broader trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Quanterix produces ultra-sensitive diagnostic devices that can detect disease biomarkers at an early stage. This chart compares its weekly performance to the market. It helps understand what's driving the stock: the general trend in biotech or news about the use of its technology in diagnostics, such as for Alzheimer's disease.
Market capitalization of the company, segment and market as a whole
QTRX - Market capitalization of the company Quanterix Corporation
Quanterix Corporation's market capitalization is a bet on its ultra-sensitive technology for detecting blood biomarkers. The company's valuation depends on the adoption of its platform in pharmaceutical research and future clinical diagnostics. The chart shows how investors assess its potential to transform disease diagnosis.
QTRX - Share of the company's market capitalization Quanterix Corporation within the market segment - Diagnostic medical equipment
Quanterix Corporation is a market leader in ultra-sensitive diagnostic tests, holding a dominant market share thanks to its Simoa technology. Its market capitalization reflects its potential for the early detection of neurodegenerative diseases and cancer.
Market capitalization of the market segment - Diagnostic medical equipment
The graph illustrates the total value of the ultra-sensitive diagnostics market. Quanterix, with its Simoa platform, is the technology leader. The dynamics in the chart demonstrate the growing demand for tools capable of detecting disease biomarkers at the earliest stages.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows the market value of ultra-sensitive diagnostics. Quanterix's market capitalization is the valuation of its technology, which enables early detection of disease biomarkers. The line illustrates how this breakthrough in testing could transform medicine and become a significant contributor to the global economy.
Book value capitalization of the company, segment and market as a whole
QTRX - Book value capitalization of the company Quanterix Corporation
This is an assessment of Quanterix Corporation's technological foundation. The chart reflects the value of its laboratory equipment and, more importantly, the patents for its ultra-sensitive Simoa® biomarker detection platform. The growth of this line reflects investments in technologies that are transforming approaches to disease diagnosis.
QTRX - Share of the company's book capitalization Quanterix Corporation within the market segment - Diagnostic medical equipment
Quanterix's physical infrastructure consists of production lines for its ultra-sensitive diagnostic devices and consumables. The chart shows the company's share of this high-tech infrastructure, which enables the detection of biomarkers at the molecular level, opening new horizons in medicine.
Market segment balance sheet capitalization - Diagnostic medical equipment
Below you can see the overall book value of the medical device sector. In this context, Quanterix, with its ultra-sensitive biomarker analysis platform, is capital-intensive. The development and production of such complex scientific instruments requires significant investment in R&D and precision manufacturing.
Book value of all companies included in the broad market index - GURU.Markets
Quanterix produces ultra-sensitive devices for measuring blood biomarkers. The company's assets include the manufacturing facilities for creating these unique analyzers and reagents. Their balance sheet represents the value of a "molecular microscope" that enables early detection of diseases, transforming healthcare.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Quanterix Corporation
Quanterix's balance sheet is the value of its production capacity for ultra-sensitive analyzers. Its market capitalization reflects its belief that its technology will become the standard in diagnostics. The MvsBCap_Co chart shows the premium for the "microscope" that can detect diseases before anyone else.
Market to book capitalization ratio in a market segment - Diagnostic medical equipment
Quanterix Corporation has developed an ultra-sensitive platform for biomarker detection, which is crucial for early disease diagnosis. The chart demonstrates how highly the market values its unique technology and its potential in neuroscience, oncology, and other areas of medicine.
Market to book capitalization ratio for the market as a whole
Quanterix Corporation has developed the ultra-sensitive Simoa platform for measuring blood biomarkers, opening up new possibilities in diagnostics and research. The company's core value lies in its unique technology. This chart illustrates why science-intensive companies in the medical diagnostics sector can command a premium valuation.
Debts of the company, segment and market as a whole
QTRX - Company debts Quanterix Corporation
For Quanterix, a company developing ultra-sensitive diagnostic tests, debt is a tool for commercializing its platform. This chart shows how the company is raising capital to expand production of its devices and reagents, as well as for marketing to pharmaceutical and research organizations. Debt accelerates innovation.
Market segment debts - Diagnostic medical equipment
Quanterix has developed an ultra-sensitive biomarker measurement platform that enables disease detection at the earliest stages. Commercializing such a complex diagnostic technology requires investment in manufacturing and marketing. This chart shows how the company is funding its expansion and implementation of its technology in research and clinical settings.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Quanterix Corporation
Quanterix develops ultra-sensitive diagnostic platforms for healthcare. This chart shows how the company balances equity and debt to fund research and commercialization. In the diagnostic equipment sector, debt can be risky if market adoption of a new technology is slower than expected.
Market segment debt to market segment book capitalization - Diagnostic medical equipment
Quanterix has developed a highly sensitive biomarker detection platform used in research and diagnostics. Commercializing this technology requires investment. The chart shows how the company's debt load compares to overall market capitalization and financial standards in the diagnostic equipment sector.
Debt to book value of all companies in the market
Quanterix (QTRX) is developing a platform for ultra-sensitive biomarker analysis, which is important for early disease diagnosis. This is a fast-growing life sciences sector. This chart shows the debt burden of the entire economy. It's interesting to consider how the company is funding its expansion and market penetration—through equity or gradual debt acquisition.
P/E of the company, segment and market as a whole
P/E - Quanterix Corporation
This metric for Quanterix, a company that has developed an ultra-sensitive platform for detecting biomarkers in blood, reflects its potential in diagnostics. The price-to-earnings ratio is likely nonexistent. The valuation depends on the adoption of its technology in pharmaceutical research and clinical practice for the early diagnosis of diseases such as Alzheimer's.
P/E of the market segment - Diagnostic medical equipment
This chart shows the average P/E valuation for diagnostic equipment manufacturers. For Quanterix, with its ultra-sensitive technology, this is an important benchmark. A P/E higher than the average would reflect a premium for its scientific leadership and potential to revolutionize early disease detection.
P/E of the market as a whole
Quanterix Corporation develops the Simoa platform for ultra-sensitive measurement of biomarkers (proteins) in the blood. The company's technology enables early disease detection and is used in research worldwide. This chart, reflecting overall sentiment, helps understand how investors view companies creating cutting-edge diagnostic tools.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Quanterix Corporation
Quanterix has developed the ultra-sensitive Simoa platform for measuring biomarkers (proteins) in the blood, opening up new possibilities for early disease diagnosis. This graph shows the expectations for this diagnostic revolution. The assessment depends on the implementation of its technology in pharmaceutical research and clinical practice, particularly in neurology and oncology.
%20P%2FE%20Quanterix%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Quanterix-Corporation&v=1772649460274 "Chart of the company's future (projected) P/E Quanterix Corporation")
Future (projected) P/E of the market segment - Diagnostic medical equipment
Quanterix developed the ultra-sensitive Simoa platform for measuring blood biomarkers. This chart compares the company's future profitability expectations with industry forecasts. It reflects the market's belief that their technology will revolutionize the diagnosis of diseases like Alzheimer's and become a standard in research.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Diagnostic-medical-equipment&v=1772649460274 "Future (projected) P/E graph of the market segment - Diagnostic medical equipment")
Future (projected) P/E of the market as a whole
Quanterix Corporation has developed an ultra-sensitive platform for biomarker detection, which is essential for early disease diagnosis. The company's growth depends on the adoption of its technology in research and medicine. This market expectation schedule influences Quanterix through R&D budgets in the pharmaceutical industry, which rise during periods of economic growth.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772649460275 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Quanterix Corporation
Quanterix has developed the ultra-sensitive Simoa platform for detecting biomarkers in blood. This technology enables early disease diagnosis and is used in neurology, oncology, and other fields. The company's profitability depends on sales of its instruments and consumables to research laboratories and pharmaceutical companies.
Profit of companies in the market segment - Diagnostic medical equipment
Quanterix has developed an ultra-sensitive platform for detecting biomarkers in blood, which is essential for early disease diagnosis. The company's success depends on the adoption of its technology in medicine and science. This graph illustrates how diagnostic innovations can transform the entire healthcare industry, impacting its future profitability through more accurate and early testing.
Overall market profit
Quanterix Corporation produces highly sensitive diagnostic devices that measure biomarkers at ultra-low concentrations. The company's technology is used in neurological disease and cancer research. Demand for its products is driven by R&D budgets in the pharmaceutical industry, which are less cyclical than the overall economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Quanterix Corporation
Quanterix has developed the ultra-sensitive Simoa platform for measuring blood biomarkers, opening up new possibilities in diagnostics. This graph reflects revenue expectations, which depend on the adoption of its technology in pharmaceutical research and clinical diagnostics, particularly in neuroscience, such as for Alzheimer's disease.
%20profit%20of%20the%20company%20Quanterix%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Quanterix-Corporation&v=1772649460322 "Graph of future (projected) profit of the company Quanterix Corporation")
Future (predicted) profit of companies in the market segment - Diagnostic medical equipment
Quanterix Corporation has developed the ultra-sensitive Simoa platform for measuring blood biomarkers, which is essential for early diagnostics and research. This chart shows the revenue forecast for the diagnostic medical equipment sector. It reflects the expected growth of the biomarker market, particularly in neurology, which is the main driver of sales of Quanterix instruments and reagents.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Diagnostic-medical-equipment&v=1772649460336 "Graph of future (predicted) profits of companies in a market segment - Diagnostic medical equipment")
Future (predicted) profit of the market as a whole
Quanterix Corporation produces highly sensitive biomarker detection tools used in drug discovery. Demand for its products depends on the R&D budgets of pharmaceutical and biotech companies. The growth forecasts shown in this chart indicate that its customers will have the resources to invest in cutting-edge scientific research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772649460344 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Quanterix Corporation
Quanterix developed the ultra-sensitive Simoa platform for measuring biomarkers (proteins) in the blood, which is important for early disease diagnosis and drug development. This chart shows how investors value its revenue from sales of devices and consumables, betting on the adoption of its technology in pharmaceutical research and clinical practice.
P/S market segment - Diagnostic medical equipment
Quanterix Corporation has developed the ultra-sensitive Simoa platform for measuring biomarkers (proteins) in blood at very low concentrations. This technology is used in research for the early diagnosis of diseases such as Alzheimer's. This chart shows the average valuation in the sector, helping to understand how the market views the potential of Quanterix's technology in medicine.
P/S of the market as a whole
Quanterix developed the highly sensitive Simoa platform for measuring blood biomarkers, enabling the early detection of diseases. The technology is used in research and diagnostics. This chart compares the lofty revenue estimates of high-tech companies with the more mundane figures of companies in traditional sectors.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Quanterix Corporation
Quanterix produces highly sensitive biomarker analysis equipment. Future revenue depends on its use in pharmaceutical research and clinical diagnostics. This chart shows how investors view the potential of its technology to accelerate drug development and early disease diagnosis.
%20P%2FS%20Quanterix%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Quanterix-Corporation&v=1772649460416 "The graph of the company's future (projected) P/S Quanterix Corporation")
Future (projected) P/S of the market segment - Diagnostic medical equipment
Quanterix Corporation has developed the ultra-sensitive Simoa platform for measuring blood biomarkers. This chart compares the company's estimated future sales with other diagnostic equipment manufacturers. It reflects investor expectations for its technology, which could revolutionize the diagnosis of neurological and other diseases.
%20P%2FS%20market%20segment%20graph%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Diagnostic-medical-equipment&v=1772649460457 "Future (projected) P/S market segment graph - Diagnostic medical equipment")
Future (projected) P/S of the market as a whole
Quanterix produces an ultra-sensitive biomarker detection platform, which is essential for early disease diagnosis. It is a tool for the future of medicine. Market optimism, reflected in this chart, is based on expectations of healthcare breakthroughs. Quanterix provides technology that can accelerate these breakthroughs, particularly in neuroscience and oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772649460491 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Quanterix Corporation
Quanterix developed the highly sensitive Simoa platform for measuring blood biomarkers, opening up new possibilities in early disease diagnosis. The company's revenue comes from sales of its devices, consumables, and laboratory services. The graph shows the growing adoption of its technology in pharmaceutical research and clinical diagnostics.
Sales of companies in the market segment - Diagnostic medical equipment
Quanterix Corporation has developed the ultra-sensitive Simoa platform for measuring blood biomarkers. This technology enables the detection of proteins at ultra-low concentrations, opening up new possibilities for the early diagnosis of diseases such as Alzheimer's. Revenue comes from the sale of instruments and consumables. This chart shows the growth of the biomedical research instruments market.
Overall market sales
Quanterix produces an ultra-sensitive biomarker detection platform used in diagnostics and drug development. Demand for its technology comes from research centers and pharmaceutical companies. This trend, reflecting economic health, impacts R&D budgets, which is a key driver for the implementation of advanced analytical tools.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Quanterix Corporation
Quanterix has developed the ultra-sensitive Simoa platform for detecting biomarkers in blood. This technology is used in early diagnosis research for diseases such as Alzheimer's. This chart shows analysts' expectations for the adoption of the Simoa platform in pharmaceutical research and clinical diagnostics.
%20sales%20of%20the%20company%20Quanterix%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Quanterix-Corporation&v=1772649460560 "Schedule of future (projected) sales of the company Quanterix Corporation")
Future (projected) sales of companies in the market segment - Diagnostic medical equipment
Quanterix Corporation has developed the ultra-sensitive Simoa platform for measuring blood biomarkers. This chart illustrates expectations for the diagnostic equipment sector. It helps analyze how the application of Quanterix technology in neurology, oncology, and other fields could change approaches to diagnostics and drug development.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Diagnostic-medical-equipment&v=1772649460573 "Schedule of future (projected) sales of companies in the market segment - Diagnostic medical equipment")
Future (projected) sales of the market as a whole
Quanterix Corporation produces a highly sensitive biomarker measurement platform used in research and diagnostics. This chart, reflecting investments in pharmaceutical R&D, is important to the company. Growing drug development budgets, particularly in neuroscience and oncology, are driving demand for Quanterix's advanced analytical tools.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772649460602 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Quanterix Corporation
Quanterix Corporation offers revolutionary technology for measuring biomarkers at ultra-low concentrations, which is critical for early disease diagnosis. The company's business is selling instruments and reagents for scientific research. This chart shows how the company is turning its unique scientific capabilities into commercial success.
Market segment marginality - Diagnostic medical equipment
Quanterix Corporation has developed the ultra-sensitive Simoa platform for measuring blood biomarkers. This technology enables the detection of diseases at the earliest stages. This graph shows how their unique diagnostic technology and business model, which includes sales of devices and consumables, impact the company's operational efficiency.
Market marginality as a whole
Quanterix Corporation has developed an ultra-sensitive biomarker measurement platform that detects proteins at the molecular level. Overall profitability is less important to them. Their business is providing tools for scientific discovery, particularly in neuroscience. Profitability depends on the adoption of their technology in R&D and clinical diagnostics.
Employees in the company, segment and market as a whole
Number of employees in the company Quanterix Corporation
Quanterix has developed an ultra-sensitive biomarker detection platform that enables disease diagnosis at the earliest stages. This chart shows its growing team. The increase reflects the expanding use of its technology in pharmaceutical research and diagnostic laboratories.
Share of the company's employees Quanterix Corporation within the market segment - Diagnostic medical equipment
Quanterix Corporation is developing the Simoa platform for ultra-sensitive biomarker measurement, opening up new possibilities in diagnostics and research. This chart shows the percentage of bioanalytical technology specialists the company attracts. It reflects its scientific leadership and the team that helps scientists see what was previously invisible.
Number of employees in the market segment - Diagnostic medical equipment
Quanterix Corporation has developed the ultra-sensitive Simoa platform for measuring blood biomarkers, opening up new possibilities in early disease diagnosis. This chart shows employment growth in the diagnostic equipment sector. The increase reflects the growing application of the technology in research, particularly in neuroscience and oncology.
Number of employees in the market as a whole
Quanterix Corporation has developed an ultra-sensitive biomarker detection platform that enables blood protein measurement at previously unattainable levels. This is a revolution in diagnostics. This graph shows overall employment, where companies like Quanterix represent a knowledge-intensive sector that creates jobs for highly skilled scientists and technicians.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Quanterix Corporation (QTRX)
Quanterix Corporation develops a platform for ultra-sensitive protein analysis, which is essential for early disease diagnosis. It's a knowledge-intensive business, where value is determined by its unique technology. This chart shows a high market capitalization per employee. The market appreciates the potential of their platform to transform medical diagnostics, and this value is generated by a team of highly qualified specialists.
%20of%20the%20company%20Quanterix%20Corporation%20(QTRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Quanterix-Corporation-QTRX&v=1772649460706 "Chart of market capitalization per employee (in thousands of dollars) of the company Quanterix Corporation (QTRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment
Quanterix produces ultra-sensitive diagnostic devices that measure biomarkers at the molecular level. In the diagnostic equipment industry, this metric reflects technological leadership. The chart shows how the market perceives the potential of the Simoa platform to transform medicine and the value it attributes to the team behind this innovation.
%20by%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Diagnostic-medical-equipment&v=1772649460711 "Market capitalization per employee (in thousands of dollars) by market segment - Diagnostic medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
Quanterix Corporation has developed the ultra-sensitive Simoa platform for measuring blood biomarkers, opening up new possibilities in early disease diagnosis. This chart reflects the high market value per employee, demonstrating the value of their unique technology for the future of medicine and pharmaceutical research.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772649460713 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Quanterix Corporation (QTRX)
Quanterix (QTRX) produces highly sensitive devices for detecting biomarkers (proteins) in blood, which is important for early diagnosis (for example, of Alzheimer's disease). It's a medical technology company. This chart shows how successfully the company sells its "razors and blades" (devices and consumables). It measures how much profit each R&D and sales employee generates.
%20Chart%20Quanterix%20Corporation%20(QTRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Quanterix-Corporation-QTRX&v=1772649460720 "Company Profit Per Employee (in thousands of dollars) Chart Quanterix Corporation (QTRX)")
Profit per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment
Quanterix is developing the Simoa platform for ultra-sensitive measurement of blood biomarkers. This technology enables disease detection at the earliest stages. This chart shows the industry benchmark and helps evaluate how effectively Quanterix is monetizing its unique diagnostic platform and consumables.
%20in%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Diagnostic-medical-equipment&v=1772649460725 "Chart of profit per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
Quanterix Corporation produces highly sensitive diagnostic platforms (Simoa technology) that can measure blood biomarkers at ultra-low concentrations. They operate a "razor and blades" model: they sell devices ("razors") and expensive consumables ("blades"). This chart shows how successfully their sales team is growing the installed base of their devices, which should lead to increased consumables revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772649460727 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Quanterix Corporation (QTRX)
Quanterix produces the ultra-sensitive Simoa platform for detecting blood biomarkers. This chart shows the commercialization of sophisticated scientific equipment. The growth in revenue per employee reflects the adoption of their technology in pharmaceutical research and clinical diagnostics, where it aids in the early detection of diseases.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Quanterix-Corporation-QTRX&v=1772649460746 "Sales chart per company employee Quanterix Corporation (QTRX)")
Sales per employee in the market segment - Diagnostic medical equipment
Quanterix (QTRX) is a company that developed a platform (Simoa) for the ultra-sensitive analysis of biomarkers (proteins) in blood. This is important for early diagnosis (for example, of Alzheimer's). This chart shows the revenue (from devices and consumables) generated by each employee. This is an indicator of the commercialization of their unique diagnostic technology.
Sales per employee for the market as a whole
Quanterix Corporation (QTRX) is the company behind the ultra-sensitive Simoa diagnostic platform. This technology enables the measurement of biomarkers at ultra-low levels. This chart shows how successfully the company sells its expensive devices (Simoa) and, more importantly, its high-margin consumables, thanks to its scientific and commercial teams.
Short shares by company, segment and market as a whole
Shares shorted by company Quanterix Corporation (QTRX)
Quanterix Corporation is a company that has developed an ultra-sensitive platform (Simoa) for measuring biomarkers (proteins) in the blood. This chart shows bearish bets. The shorts may be driven by doubts about the speed of commercialization of their technology or the demand for their devices (which are very expensive) beyond narrow scientific research.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Quanterix-Corporation-QTRX&v=1772649460826 "Short Shares Chart for the Company Quanterix Corporation (QTRX)")
Shares shorted by market segment - Diagnostic medical equipment
Quanterix (QTRX) is a company that has developed an ultra-sensitive platform (Simoa) for measuring biomarkers (proteins) in the blood, which is important for diagnostics (for example, for Alzheimer's). This chart shows bets against the "scientific equipment" sector. Its rise reflects concerns that R&D budgets of pharmaceutical companies and laboratories (QTRX's clients) will be cut due to the recession.
Shares shorted by the overall market
Quanterix Corporation (QTRX) develops ultra-sensitive platforms for bioanalysis (e.g., diagnostics). It's a science-intensive business that sells equipment to researchers. When this chart shows rising fear, investors fear that biotech and pharmaceutical companies (QTRX's clients) will cut R&D budgets and purchase new equipment.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Quanterix Corporation (QTRX)
Quanterix is a manufacturer of ultra-sensitive equipment (Simoa) for biomarker analysis, which is critical for neuroscience R&D. This chart measures investor confidence in their technology. It shows when the stock is overbought due to expectations of an R&D boom or oversold due to doubts about commercialization.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Quanterix-Corporation-QTRX&v=1772649460906 "RSI 14 indicator chart for the company's stock Quanterix Corporation (QTRX)")
RSI 14 Market Segment - Diagnostic medical equipment
Quanterix is the company behind Simoa technology, a highly sensitive platform that can measure individual proteins (biomarkers) in the blood. This is used for early diagnosis (for example, for Alzheimer's). This chart measures the overall momentum in the life sciences sector. It helps understand whether the sector is overheated by expectations of breakthroughs.
RSI 14 for the overall market
Quanterix, a company developing ultra-sensitive diagnostics, sees this chart as representing the R&D budgets of its clients (biotech companies). In the euphoria of the moment, biotech companies are generously funding and spending on QTRX equipment for research. In a panic, the funding for biotech companies is shut off, and budgets for "auxiliary" software and R&D are cut.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast QTRX (Quanterix Corporation)
Quanterix has developed an ultra-sensitive platform (Simoa) for measuring biomarkers (proteins) in the blood, which is critical for diagnosing conditions such as Alzheimer's disease. This chart shows the average analyst forecast. Their targets are based on sales of instruments and consumables to laboratories and pharmaceutical companies.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-QTRX-Quanterix-Corporation&v=1772649460947 "A chart showing analyst consensus forecasts for the expected stock price. QTRX (Quanterix Corporation)")
The difference between the consensus estimate and the actual stock price QTRX (Quanterix Corporation)
Quanterix (QTRX) is a company whose Simoa technology measures biomarkers (proteins) in the blood at ultra-low concentrations, promising a breakthrough in Alzheimer's diagnostics. This chart shows the valuation of their technology. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their diagnostic platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-QTRX-Quanterix-Corporation&v=1772649460951 "A chart showing the difference between the consensus forecast and the actual stock price. QTRX (Quanterix Corporation)")
Analyst consensus forecast for stock prices by market segment - Diagnostic medical equipment
Quanterix (QTRX) is a company whose "Simoa" technology measures biomarkers (proteins) in the blood with ultra-high sensitivity. This represents a breakthrough in Alzheimer's diagnostics and R&D. This chart shows general expectations for the diagnostic equipment sector. It reflects whether experts believe in a "liquid biopsy" boom for the brain.
Analysts' consensus forecast for the overall market share price
Quanterix Corporation has developed technology (Simoa) for the ultra-sensitive measurement of biomarkers (proteins) in blood, which promises a breakthrough in early diagnostics (for example, for Alzheimer's disease). This graph illustrates the overall "risk appetite." For Quanterix, a company with a revolutionary diagnostic platform, overall market optimism is important for funding research and commercialization.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Quanterix Corporation
Quanterix (QTRX) is a protein microscope. Their platform (Simoa) is an ultra-sensitive diagnostic tool that can measure minute concentrations of protein biomarkers in the blood, which is critical for the early detection of Alzheimer's and other diseases. This chart is an assessment of their razor and blades. It reflects their ability to sell razors (the devices) and their growing revenue from blades (the consumables).
AKIMA Market Segment Index - Diagnostic medical equipment
Quanterix is changing the diagnostics game by using its ultra-sensitive Simoa platform to detect molecular-level biomarkers (for example, for Alzheimer's disease). This chart shows the average index for the diagnostics sector, helping investors understand how Quanterix's technology outperforms the industry average.
The AKIM Index for the overall market
Quanterix is a company that has developed an ultra-sensitive technology (Simoa) for detecting blood biomarkers (neurology, oncology). This chart, which reflects the market average, is a backdrop. It helps assess how this research tools provider compares to overall macroeconomic trends and R&D budgets.
